by The leishmaniasis treatment market is expanding rapidly due to increasing research investments from governments and pharmaceutical companies. Leishmaniasis is a vector-borne tropical disease caused by Leishmania parasites. It affects millions of people globally with atypical clinical manifestations ranging from self-healing cutaneous lesions to fatal visceral infections if left untreated. Existing treatment options for leishmaniasis such as pentavalent antimonials have issues related to drug resistance, toxicity and long treatment durations. This has necessitated research into more effective and safer treatment options.
The global leishmaniasis treatment market is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Global Leishmaniasis Treatment Market Size are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. These players dominate the market with established drugs and active pipelines.
The market is witnessing growing demand driven by rising prevalence of leishmaniasis infections globally especially in subtropical and tropical regions. Factors such as population growth, increased immigration, socioeconomic changes and environmental degradation have contributed to the rising disease incidence.
Several pharmaceutical companies are also actively exploring opportunities for geographical expansion into emerging markets. This includes regulatory filings and partnerships with local players. For instance, Azafaros B.V recently collaborated with Tunisian company Siphat to increase access to leishmaniasis treatment in North Africa and the Middle East.
Market key trends
One of the key trends driving growth in the leishmaniasis treatment market is increasing research investments into nanomedicine and targeted drug delivery approaches. Nanocarrier systems could help overcome issues associated with existing systemic drugs such as resistance, toxicity and instability. Researchers are exploring use of nanoparticles, liposomes and other novel drug formulations to improve treatment efficacy via targeted delivery to infected macrophages and lesions. This holds promise to transform leishmaniasis management.
Porter’s Analysis
Threat of new entrants: new companies may find it difficult to enter the market due to high capital requirement and long gestation period required for R&D.
Bargaining power of buyers: buyers have low bargaining power as approved treatment options are limited.
Bargaining power of suppliers: suppliers have moderate bargaining power due to niche nature of therapies and drugs.
Threat of new substitutes: threat from new substitutes is low as there are limited treatment options available for leishmaniasis.
Competitive rivalry: exists among existing players to retain market share through product innovations.
Geographical Regions
North America region accounts for the major share of the global leishmaniasis treatment market in terms of value, owing to high cases of leishmaniasis infection and better reimbursement scenario. The region spends heavily on R&D to develop advanced therapies.
Asia Pacific region is poised to grow at the fastest rate during the forecast period. This is attributed to factors such as growing awareness among patients, increasing healthcare expenditure, presence of generic drug manufacturers, and rampant incidence of leishmaniasis infection especially in developing countries such as India and Bangladesh.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
